HK1109634A1 - Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen - Google Patents

Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen

Info

Publication number: HK1109634A1
Authority: HK; Hong Kong
Prior art keywords: chimeric; human; differentiation antigen; radiolabeled antibodies; restricted differentiation
Prior art date: 1992-11-13

Application number

HK08100410.4A

Other languages

English (en)

Inventor

Darrell R Anderson

Nabil Hanna

John E Leonard

Roland A Newman

Mitchell E Reff

William M Rastetter

Original Assignee

Biogen Idec Inc

Idec

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

2008-01-11

Publication date

2008-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1109634(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-11 Application filed by Biogen Idec Inc, Idec filed Critical Biogen Idec Inc

2008-06-13 Publication of HK1109634A1 publication Critical patent/HK1109634A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HK08100410.4A 1992-11-13 2008-01-11 Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen HK1109634A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US97889192A	1992-11-13	1992-11-13

Publications (1)

Publication Number	Publication Date
HK1109634A1 true HK1109634A1 (en)	2008-06-13

Family

ID=25526490

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HK08100410.4A HK1109634A1 (en)	1992-11-13	2008-01-11	Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
HK08100409.7A HK1109633A1 (en)	1992-11-13	2008-01-11	Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
HK09104369.6A HK1125574A1 (en)	1992-11-13	2009-05-13	Chimeric anti-cd20 antibody

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
HK08100409.7A HK1109633A1 (en)	1992-11-13	2008-01-11	Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
HK09104369.6A HK1125574A1 (en)	1992-11-13	2009-05-13	Chimeric anti-cd20 antibody

Country Status (24)

Country	Link
US (2)	US5736137A (xx)
EP (1)	EP2000149B1 (xx)
KR (1)	KR100365632B1 (xx)
CN (5)	CN101007851B (xx)
AT (2)	ATE421335T1 (xx)
BR (1)	BR1100622A (xx)
CA (1)	CA2626445A1 (xx)
DE (3)	DE69334259D1 (xx)
DK (2)	DK2000149T3 (xx)
ES (2)	ES2326144T3 (xx)
FR (1)	FR04C0018I2 (xx)
GE (3)	GEP20074162B (xx)
HK (3)	HK1109634A1 (xx)
HU (1)	HU219264B (xx)
IL (1)	IL107591A (xx)
LU (1)	LU91620I2 (xx)
MY (1)	MY111196A (xx)
NL (1)	NL300424I1 (xx)
PL (1)	PL175557B1 (xx)
PT (2)	PT2000149E (xx)
SG (1)	SG45294A1 (xx)
TW (1)	TW376320B (xx)
UA (1)	UA27946C2 (xx)
ZA (1)	ZA938466B (xx)

Families Citing this family (715)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JP3095175B2 (ja) *	1992-11-13	2000-10-03	アイデックファーマシューティカルズコーポレイション	Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) *	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) *	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
WO1996004925A1 (en) *	1994-08-12	1996-02-22	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US20030180290A1 (en) *	1995-06-07	2003-09-25	Idec Pharmaceuticals Corporation	Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en)	1999-05-14	2002-04-16	Zight Corporation	Time sequential lookup table arrangement for a display
US6893636B2 (en) *	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en)	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6991790B1 (en) *	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
US20020088019A1 (en) *	1997-09-02	2002-07-04	Oron Yacoby-Zeevi	Methods of and pharmaceutical compositions for improving implantation of embryos
US6562950B2 (en) *	1997-09-02	2003-05-13	Insight Strategy & Marketing Ltd.	Heparanase activity neutralizing anti-heparanase monoclonal antibody
US20010006630A1 (en) *	1997-09-02	2001-07-05	Oron Yacoby-Zeevi	Introducing a biological material into a patient
US6699672B1 (en)	1997-09-02	2004-03-02	Insight Biopharmaceuticals Ltd.	Heparanase specific molecular probes and their use research and medical applications
US6177545B1 (en) *	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
US20040213789A1 (en) *	1997-09-02	2004-10-28	Oron Yacoby-Zeevi	Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20030161823A1 (en) *	1998-08-31	2003-08-28	Neta Ilan	Therapeutic and cosmetic uses of heparanases
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
EP1071700B1 (en) *	1998-04-20	2010-02-17	GlycArt Biotechnology AG	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1974747E (pt)	1998-08-11	2012-09-05	Biogen Idec Inc	Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US20030217375A1 (en) *	1998-08-31	2003-11-20	Eyal Zcharia	Transgenic animals expressing heparanase and uses thereof
US20010033839A1 (en) *	1999-10-04	2001-10-25	Emilio Barbera-Guillem	Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6224866B1 (en)	1998-10-07	2001-05-01	Biocrystal Ltd.	Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DK1616572T3 (da)	1998-11-09	2010-12-06	Biogen Idec Inc	Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
JP2002529429A (ja) *	1998-11-09	2002-09-10	アイデック・ファーマシューティカルズ・コーポレイション	Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
WO2000029431A1 (en) *	1998-11-17	2000-05-25	Tanox, Inc.	Bispecific molecules cross-linking itim and itam for therapy
EP1141024B1 (en) *	1999-01-15	2018-08-08	Genentech, Inc.	POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
AU2878600A (en) *	1999-03-01	2000-09-21	Hadasit Medical Research Services & Development Company Ltd	Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
KR20020027311A (ko) *	1999-05-07	2002-04-13	제넨테크, 인크.	Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
SI1176981T1 (sl)	1999-05-07	2006-04-30	Genentech Inc	Zdravljenje avtoimunskih bolezni z antagonisti, ki se vezejo na B celicne povrsinske markerje
EP1194167B1 (en) *	1999-06-09	2009-08-19	Immunomedics, Inc.	Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (it) *	1999-06-11	2000-12-11	Consiglio Nazionale Ricerche	Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US6949245B1 (en) *	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
MXPA01013395A (es) *	1999-06-25	2003-09-04	Genentech Inc	Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
PL201086B1 (pl) *	1999-07-12	2009-03-31	Genentech Inc	Zastosowanie przeciwciał wiążących się z antygenem CD20
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) *	1999-08-11	2002-09-17	Idec Pharmaceuticals Corporation	Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) *	1999-08-23	2001-03-19	Biocrystal Limited	Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2003513937A (ja) *	1999-11-08	2003-04-15	アイデック・ファーマシューティカルズ・コーポレイション	抗ｃｄ２０抗体および／または化学療法薬および放射線療法と併用して抗ｃｄ４０ｌ抗体を使用するｂ細胞悪性疾患の処置
AU2001264612C1 (en) *	1999-11-08	2007-11-22	Biogen Idec Inc.	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1255558B1 (en) *	2000-02-16	2006-06-14	Genentech, Inc.	Anti-april antibodies and hybridoma cells
US20030185796A1 (en) *	2000-03-24	2003-10-02	Chiron Corporation	Methods of therapy for non-hodgkin's lymphoma
US6896885B2 (en) *	2000-03-31	2005-05-24	Biogen Idec Inc.	Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
US20020004587A1 (en)	2000-04-11	2002-01-10	Genentech, Inc.	Multivalent antibodies and uses therefor
CA2399940A1 (en)	2000-04-13	2001-10-25	The Rockefeller University	Enhancement of antibody-mediated immune responses
BR0110364A (pt) *	2000-04-25	2003-12-30	Idec Pharma Corp	Administração intratecal de rituximab para tratamento de linfomas do sistema nervoso central
WO2001083781A2 (en) *	2000-04-28	2001-11-08	Millennium Pharmaceuticals, Inc.	14094, a novel human trypsin family member and uses thereof
ES2331646T3 (es) *	2000-05-19	2010-01-12	Genentech, Inc.	Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
CA2411102A1 (en) *	2000-06-20	2001-12-27	Idec Pharmaceutical Corporation	Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
EP1292334A4 (en) *	2000-06-22	2003-11-19	Idec Pharma Corp	BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS
US20060034830A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060024304A1 (en) *	2000-06-28	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060034828A1 (en) *	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060029604A1 (en) *	2000-06-28	2006-02-09	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
CN1592645A (zh) *	2000-09-18	2005-03-09	拜奥根Idec公司	使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US20020128448A1 (en) *	2000-10-20	2002-09-12	Idec Pharmaceuticals Corporation	Variant IgG3 Rituxan and therapeutic use thereof
US7507724B2 (en)	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7906492B2 (en) *	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CN1268394C (zh) *	2001-01-17	2006-08-09	特鲁比昂药品公司	结合域－免疫球蛋白融合蛋白
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
AU2008200400B2 (en) *	2001-01-17	2012-06-07	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en) *	2001-01-31	2002-10-31	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) *	2002-01-31	2003-11-13	Kandasamy Hariharan	Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) *	2001-11-09	2003-06-05	Kandasamy Hariharan	Immunoregulatory antibodies and uses thereof
KR20080087184A (ko)	2001-01-31	2008-09-30	바이오겐 아이덱 인크.	종양질환 치료를 위한 ｃｄ23 길항제의 용도
WO2002060485A2 (en)	2001-01-31	2002-08-08	Idec Pharmaceuticals Corporation	Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20070065436A1 (en) *	2001-01-31	2007-03-22	Biogen Idec Inc.	Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
CA2442801A1 (en) *	2001-04-02	2002-10-10	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with gntiii
EP1383532B1 (en)	2001-04-02	2011-05-04	Genentech, Inc.	Combination therapy
JP2004527528A (ja) *	2001-04-09	2004-09-09	プロジェニクス・ファーマスーティカルズ・インコーポレイテッド	抗ｃｄ１９免疫毒素
US20020193569A1 (en) *	2001-06-04	2002-12-19	Idec Pharmaceuticals Corporation	Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CA2447791A1 (en) *	2001-06-13	2002-12-19	Neslihan Delacruz	Methods of culturing animal cells and polypeptide production in animal cells
JP2005510208A (ja) *	2001-08-03	2005-04-21	ジェネンテック・インコーポレーテッド	ＴＡＣＩｓ及びＢＲ３ポリペプチドとその用途
NZ581474A (en) *	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016470A2 (en) *	2001-08-10	2003-02-27	University Of Virginia Patent Foundation	Enhancing the efficacy of immunotherapies by supplementing with complement
US7205048B2 (en) *	2001-09-17	2007-04-17	Invitrogen Corporation	Functionalized fluorescent nanocrystal compositions and methods of making
EP2159044B1 (en) *	2001-09-17	2012-05-16	Life Technologies Corporation	Nanocrystals
US7214428B2 (en) *	2001-09-17	2007-05-08	Invitrogen Corporation	Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
ATE443259T1 (de)	2001-09-20	2009-10-15	Univ Texas	Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
DK2279755T3 (da)	2001-10-10	2014-05-26	Ratiopharm Gmbh	Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
US20050069962A1 (en)	2001-10-12	2005-03-31	Archer Robert M	Antibody complexes and methods for immunolabeling
US8323903B2 (en) *	2001-10-12	2012-12-04	Life Technologies Corporation	Antibody complexes and methods for immunolabeling
ES2311634T3 (es) *	2001-10-19	2009-02-16	Centre Hospitalier Regional Et Universitaire De Tours	Procedimientos y composiciones para evaluar la respuesta a un tratamiento de anticuerpo.
NZ532526A (en) *	2001-10-25	2007-01-26	Genentech Inc	Compositions comprising a glycoprotein having a Fc region
US6671189B2 (en) *	2001-11-09	2003-12-30	Minebea Co., Ltd.	Power converter having primary and secondary side switches
DE60230918D1 (de)	2001-11-16	2009-03-05	Biogen Idec Inc	Polycistronische expression von antikörpern in cho zellen
US20060024292A1 (en) *	2001-12-27	2006-02-02	Gerngross Tillman U	Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
EP1472275B1 (en)	2002-02-05	2008-12-17	Genentech, Inc.	Protein purification
JP2005517025A (ja)	2002-02-08	2005-06-09	エクサイトセラピーズ，インコーポレイテッド	免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
EP1519959B1 (en) *	2002-02-14	2014-04-02	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) *	2002-02-14	2012-10-16	Immunomedics, Inc.	Structural variants of antibodies for improved therapeutic characteristics
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
EP1483294B2 (en) *	2002-03-01	2019-10-30	Immunomedics, Inc.	Internalizing anti-cd74 antibodies and methods of use
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8361464B2 (en)	2002-03-01	2013-01-29	Immunomedics, Inc.	Anthracycline-Antibody Conjugates for Cancer Therapy
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US8093357B2 (en) *	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20030180292A1 (en) *	2002-03-14	2003-09-25	Idec Pharmaceuticals	Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
EP1501369B1 (en)	2002-04-26	2015-06-24	Genentech, Inc.	Non-affinity purification of proteins
BR0313033A (pt) *	2002-07-25	2007-07-10	Genentech Inc	anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
US8187593B2 (en) *	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) *	2002-08-14	2011-10-25	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) *	2002-08-14	2012-06-05	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
EP3150630A1 (en)	2002-09-27	2017-04-05	Xencor Inc.	Optimized fc variants and methods for their generation
DK3284753T3 (da) *	2002-10-17	2021-07-05	Genmab As	Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
JP4033390B2 (ja) *	2002-10-30	2008-01-16	独立行政法人科学技術振興機構	不死化ナチュラルキラー細胞株
EP1572972A4 (en) *	2002-11-21	2007-11-21	Genentech Inc	THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
SE0203731D0 (sv) *	2002-12-13	2002-12-13	Mitra Medical Technology Ab	Reagent
BRPI0316779B1 (pt) *	2002-12-16	2020-04-28	Genentech Inc	anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
CA2512729C (en) *	2003-01-09	2014-09-16	Macrogenics, Inc.	Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4177123B2 (ja) *	2003-01-10	2008-11-05	富士通株式会社	配線図形検証方法、プログラム及び装置
US20040202666A1 (en) *	2003-01-24	2004-10-14	Immunomedics, Inc.	Anti-cancer anthracycline drug-antibody conjugates
AU2004207538A1 (en) *	2003-01-27	2004-08-12	Biogen Idec Ma Inc.	Compositions and methods for treating cancer using IGSF9 and LIV-1
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) *	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
RU2358762C9 (ru)	2003-04-09	2016-10-10	Джинентех, Инк.	Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
US9416187B2 (en) *	2003-05-09	2016-08-16	Duke University	CD-20 specific antibodies and methods of employing same
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
PL2272868T4 (pl) *	2003-06-05	2016-07-29	Genentech Inc	Terapia skojarzona zaburzeń B-komórkowych
WO2004108065A2 (en) *	2003-06-09	2004-12-16	Insight Biopharmaceuticals Ltd.	Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
DK1648940T3 (en)	2003-07-28	2016-08-15	Genentech Inc	Reduction of leaching of protein A during protein A affinity chromatography
AU2004264601A1 (en) *	2003-07-29	2005-02-24	Genentech, Inc.	Assay for human anti CD20 antibodies and uses therefor
RU2006110036A (ru) *	2003-08-29	2006-08-10	Дженентек, Инк. (Us)	Лечение глазных расстройств анти-cd20
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US20060134105A1 (en) *	2004-10-21	2006-06-22	Xencor, Inc.	IgG immunoglobulin variants with optimized effector function
US8399618B2 (en)	2004-10-21	2013-03-19	Xencor, Inc.	Immunoglobulin insertions, deletions, and substitutions
US8883147B2 (en)	2004-10-21	2014-11-11	Xencor, Inc.	Immunoglobulins insertions, deletions, and substitutions
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
CN100453556C (zh)	2003-10-16	2009-01-21	麦克罗梅特股份公司	多特异性的去免疫化cd3结合物
EP2236172A1 (en)	2003-11-04	2010-10-06	Novartis Vaccines and Diagnostics, Inc.	Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
SG148161A1 (en) *	2003-11-05	2008-12-31	Palingen Inc	Enhanced b cell cytotoxicity of cdim binding antibody
CN102373214B (zh) *	2003-11-05	2014-07-09	罗氏格黎卡特股份公司	具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
JP2008504002A (ja)	2003-11-12	2008-02-14	バイオジェン・アイデック・エムエイ・インコーポレイテッド	新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
CN1914226B (zh) *	2003-11-25	2012-02-01	达纳-法伯癌症研究院有限公司	SARS-CoV抗体及其使用方法
JP2007514787A (ja) *	2003-12-19	2007-06-07	ジェネンテック・インコーポレーテッド	自己免疫疾患の治療におけるｃｄ２０の検出
US20050191297A1 (en) *	2003-12-19	2005-09-01	Genentech, Inc.	Detection of CD20 in transplant rejection
FR2867982B1 (fr) *	2004-03-26	2007-07-20	Jean Marie Andrieu	Procede pour amplifier l'activite de vaccins therapeutiques
ZA200608572B (en) *	2004-04-16	2008-06-25	Genentech Inc	Assay for antibodies
RU2006140374A (ru) *	2004-04-16	2008-05-27	Дженентек, Инк. (Us)	Лечение нарушений
CN101005854A (zh) *	2004-04-16	2007-07-25	健泰科生物技术公司	用于增进b细胞消除的方法
WO2005103081A2 (en) *	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
RU2006142857A (ru) *	2004-05-05	2008-06-10	Дженентек, Инк. (Us)	Профилактика аутоиммунного заболевания
EP2428216A3 (en)	2004-05-20	2012-05-23	ZymoGenetics, Inc.	Methods of treating cancer using IL-21 and monoclonal antibody therapy
WO2005117978A2 (en) *	2004-06-04	2005-12-15	Genentech, Inc.	Method for treating multiple sclerosis
PA8635501A1 (es) *	2004-06-04	2006-06-02	Genentech Inc	Uso de un anticuerpo para el tratamiento del lupus
US9109255B2 (en) *	2004-06-18	2015-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for determining responsiveness to antibody therapy
AU2005272993B2 (en)	2004-07-15	2010-02-11	Xencor, Inc.	Optimized Fc variants
EP1781378A2 (en) *	2004-07-22	2007-05-09	Genentech, Inc.	Method of treating sjögren's syndrome
ES2531155T3 (es)	2004-07-23	2015-03-11	Genentech Inc	Cristalización de anticuerpos anti-VEGF
DK1776384T3 (da)	2004-08-04	2013-09-02	Mentrik Biotech Llc	VARIANT-Fc-REGIONER
JP2008510852A (ja) *	2004-08-17	2008-04-10	インヴィトロジェンコーポレーション	高発光性コロイド粒子の合成
JP2008510466A (ja) *	2004-08-19	2008-04-10	ジェネンテック・インコーポレーテッド	エフェクター機能が変更しているポリペプチド変異体
KR101247908B1 (ko) *	2004-09-02	2013-03-26	제넨테크, 인크.	항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
US7655229B2 (en) *	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) *	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
BRPI0515615A (pt) *	2004-09-08	2008-07-29	Genentech Inc	métodos para tratar células cancerosas e doença imune relacionada
CN101048428A (zh) *	2004-09-08	2007-10-03	健泰科生物技术公司	利用死亡受体配体和cd20抗体的方法
EP1812060A2 (en) *	2004-10-05	2007-08-01	Genentech, Inc.	Method for treating vasculitis
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EP2305775A3 (en)	2004-10-29	2011-06-08	Molecular Probes, Inc.	Functionalized fluorescent nanocrystals, and methods for their preparation and use
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
EP2332985A3 (en)	2004-11-12	2012-01-25	Xencor, Inc.	Fc variants with altered binding to FcRn
GB2420976B (en) *	2004-11-19	2006-12-20	Zvi Finkelstein	Therapeutic implant
MX2007007165A (es) *	2004-12-17	2007-08-14	Genentech Inc	Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior.
NZ556635A (en)	2004-12-22	2010-11-26	Genentech Inc	Method for producing soluble multi-membrane-spanning proteins
EP1674479A1 (en) *	2004-12-22	2006-06-28	Memorial Sloan-Kettering Cancer Center	Modulation of Fc Gamma receptors for optimizing immunotherapy
AU2005318407B2 (en) *	2004-12-23	2009-11-05	F. Hoffmann-La Roche Ag	Detection of a therapeutic antibody in an experimental animal
ES2327840T3 (es)	2004-12-23	2009-11-04	Gpc Biotech Ag	Derivados de acido escuarico con actividad antiproliferativa.
JP2008526234A (ja)	2005-01-05	2008-07-24	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｃｒｉｐｔｏ結合分子
GT200600020A (es) *	2005-01-13	2006-11-08		Procedimiento de tratamiento
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
AR053579A1 (es) *	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9284375B2 (en) *	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
WO2006113665A2 (en) *	2005-04-15	2006-10-26	Macrogenics, Inc.	Covalent diabodies and uses thereof
WO2012018687A1 (en)	2010-08-02	2012-02-09	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP1874350A2 (en) *	2005-04-22	2008-01-09	Genentech, Inc.	Method for treating dementia or alzheimer's disease with a cd20 antibody
US8034902B2 (en) *	2005-05-04	2011-10-11	Quark Pharmaceuticals, Inc.	Recombinant antibodies against CD55 and CD59 and uses thereof
EP1888649A2 (en) *	2005-05-09	2008-02-20	GlycArt Biotechnology AG	Antigen binding molecules having modified fc regions and altered binding to fc receptors
JP2008545958A (ja) *	2005-05-20	2008-12-18	ジェネンテック・インコーポレーテッド	自己免疫性疾患の被検体の生体試料の前処理
CA2609731A1 (en) *	2005-05-24	2006-11-30	Avestha Gengraine Technologies Pvt Ltd.	A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
MX2008000253A (es)	2005-07-08	2008-04-02	Biogen Idec Inc	Anticuerpos de sp35 y usos de los mismos.
US20080279850A1 (en) *	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HUE026303T2 (hu) *	2005-07-25	2016-06-28	Emergent Product Dev Seattle	B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
CN101267836A (zh)	2005-07-25	2008-09-17	特鲁比昂药品公司	单剂量cd20特异性结合分子的用途
DK2573114T3 (en)	2005-08-10	2016-07-04	Macrogenics Inc	The identification and production of antibodies with variant Fc regions, and methods of using same
NZ597168A (en)	2005-08-19	2013-07-26	Abbott Lab	Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP2500358A3 (en)	2005-08-19	2012-10-17	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
JP2009507040A (ja) *	2005-09-02	2009-02-19	グライコフィ，インコーポレイテッド	主としてｇｌｃｎａｃｍａｎ３ｇｌｃｎａｃ２糖形態を含む免疫グロブリン
AU2006299429B2 (en)	2005-10-03	2012-02-23	Xencor, Inc.	Fc variants with optimized Fc receptor binding properties
WO2007056411A2 (en) *	2005-11-08	2007-05-18	Genentech, Inc.	Method of producing pan-specific antibodies
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
EP1952150B1 (en) *	2005-11-23	2016-12-14	Genentech, Inc.	Methods and compositions related to b cell assays
WO2007064911A1 (en) *	2005-12-02	2007-06-07	Biogen Idec Inc.	Anti-mouse cd20 antibodies and uses thereof
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
WO2007102200A1 (ja) *	2006-03-07	2007-09-13	Osaka University	抗ｃｄ２０モノクローナル抗体
JP2009529331A (ja) *	2006-03-10	2009-08-20	マクロジェニクス，インコーポレーテッド	変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
MX2008012013A (es)	2006-03-23	2008-10-03	Novartis Ag	Tratamiento con anticuerpo antigeno de celulas neoplasicas.
US8592149B2 (en)	2006-04-27	2013-11-26	Pikamab, Inc.	Methods and compositions for antibody therapy
US20080118978A1 (en)	2006-04-28	2008-05-22	Takashi Sato	Anti-tumor agent
US7727525B2 (en) *	2006-05-11	2010-06-01	City Of Hope	Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CA2660592C (en)	2006-05-26	2016-07-12	Macrogenics, Inc.	Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CN105837690A (zh) *	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
LT2029173T (lt)	2006-06-26	2016-11-10	Macrogenics, Inc.	Fc riib specifiniai antikūnai ir jų panaudojimo būdai
CA2656224C (en)	2006-06-26	2018-01-09	Macrogenics, Inc.	Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20080058922A1 (en) *	2006-08-31	2008-03-06	Cardiac Pacemakers, Inc.	Methods and devices employing vap-1 inhibitors
US8636995B2 (en) *	2006-08-31	2014-01-28	Cardiac Pacemakers, Inc.	Methods and devices to regulate stem cell homing
US8372399B2 (en) *	2006-08-31	2013-02-12	Cardiac Pacemakers, Inc.	Bispecific antibodies and agents to enhance stem cell homing
US20080112961A1 (en) *	2006-10-09	2008-05-15	Macrogenics, Inc.	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en) *	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008079302A2 (en) *	2006-12-21	2008-07-03	Millipore Corporation	Purification of proteins
US8362217B2 (en)	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
US8569464B2 (en) *	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
DK2099826T3 (da)	2007-01-05	2014-01-20	Univ Zuerich	Anti-beta-amyloid-antistof og anvendelser deraf
AU2008205244B2 (en)	2007-01-09	2013-02-07	Biogen Ma Inc.	Sp35 antibodies and uses thereof
DE102007001370A1 (de) *	2007-01-09	2008-07-10	Curevac Gmbh	RNA-kodierte Antikörper
JP5361738B2 (ja)	2007-01-22	2013-12-04	ジェネンテック，インコーポレイテッド	多価電解質沈殿物及びタンパク質の精製
US8450348B2 (en) *	2007-02-21	2013-05-28	Forma Tm, Llc	Derivatives of squaric acid with anti-proliferative activity
EP3202786A3 (en)	2007-03-12	2017-10-11	ESBATech, an Alcon Biomedical Research Unit LLC	Sequence based engineering and optimization of single chain antibodies
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) *	2007-04-02	2008-10-09	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selenocysteine mediated hybrid antibody molecules
FR2915398B1 (fr) *	2007-04-25	2012-12-28	Lab Francais Du Fractionnement	"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (en) *	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
EP2019101A1 (en) *	2007-07-26	2009-01-28	GPC Biotech AG	Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
AU2008267733B2 (en) *	2007-06-25	2013-11-14	Esbatech, An Alcon Biomedical Research Unit Llc	Sequence based engineering and optimization of single chain antibodies
CN103435696B (zh)	2007-06-25	2016-10-12	艾斯巴技术-诺华有限责任公司	修饰抗体的方法和具有改善的功能性质的修饰抗体
US10745701B2 (en)	2007-06-28	2020-08-18	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) *	2008-06-30	2009-12-31	The Trustees Of Princeton University	Methods of identifying and treating poor-prognosis cancers
KR101643514B1 (ko)	2007-07-09	2016-07-27	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
MX2010000970A (es) *	2007-07-31	2010-03-09	Regeneron Pharma	Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
MX2010002406A (es) *	2007-09-05	2010-04-27	Hoffmann La Roche	Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
CA2715080C (en)	2007-09-28	2021-09-28	Intrexon Corporation	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US20090098118A1 (en) *	2007-10-15	2009-04-16	Thomas Friess	Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2200631A1 (en)	2007-10-16	2010-06-30	Zymogenetics, Inc.	Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
AU2008316276A1 (en) *	2007-10-22	2009-04-30	Oncolytics Biotech Inc.	Treatment regime for proliferative disorders
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2840090B1 (en)	2007-10-30	2018-02-21	Genentech, Inc.	Antibody purification by cation exchange chromatography
US8795667B2 (en) *	2007-12-19	2014-08-05	Macrogenics, Inc.	Compositions for the prevention and treatment of smallpox
CN101945667A (zh) *	2007-12-21	2011-01-12	健泰科生物技术公司	利妥昔单抗不应性类风湿性关节炎患者的疗法
EP3575317A1 (en)	2007-12-26	2019-12-04	Xencor, Inc.	Fc variants with altered binding to fcrn
EP2077281A1 (en)	2008-01-02	2009-07-08	Bergen Teknologioverforing AS	Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en)	2008-01-02	2011-03-29	Bergen Teknologieverforing As	B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2085095B1 (en)	2008-01-17	2012-03-07	Philogen S.p.A.	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
WO2009097095A2 (en) *	2008-01-28	2009-08-06	The Regents Of The University Of California	Methods for treating hematopoietic malignancies
LT2268310T (lt) *	2008-03-25	2016-09-26	Roche Glycart Ag	Panaudojimas ii tipo anti-cd20 antikūnų su padidėjusiu nuo antikūnų priklausomu ląsteliniu citotoksiškumu (adcc) derinyje su ciklofosfamidu, vinkristinu ir doksorubicinu ne-hodžkino limfomos gydymui
KR101614494B1 (ko)	2008-04-02	2016-04-22	마크로제닉스, 인크.	Ｂｃｒ-복합체-특이적 항체 및 그것의 사용 방법
SI2247304T1 (sl)	2008-04-02	2016-11-30	Macrogenics, Inc.	Protitelesa, specifična za HER2/neu, in postopki za njihovo uporabo
MX340204B (es)	2008-04-11	2016-06-30	Emergent Product Dev Seattle	Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
EP2112152A1 (en)	2008-04-22	2009-10-28	GPC Biotech AG	Dihydropteridinones as Plk Inhibitors
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009134738A1 (en) *	2008-04-29	2009-11-05	Genentech, Inc.	Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
NZ588554A (en)	2008-04-29	2013-03-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en)	2008-06-03	2013-07-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) *	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
ES2675730T3 (es) *	2008-06-04	2018-07-12	Macrogenics, Inc.	Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
US8999702B2 (en) *	2008-06-11	2015-04-07	Emd Millipore Corporation	Stirred tank bioreactor
WO2009155725A1 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	Solubility optimization of immunobinders
EP3266453A1 (en)	2008-07-03	2018-01-10	Mayo Foundation for Medical Education and Research	Treating cancer
KR101054362B1 (ko)	2008-07-03	2011-08-05	재단법인 목암생명공학연구소	재조합 단백질의 푸코스 함량을 감소시키는 방법
RU2011104348A (ru) *	2008-07-08	2012-08-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
JP2011527572A (ja)	2008-07-09	2011-11-04	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｌｉｎｇｏ抗体または断片を含む組成物
KR101030978B1 (ko) *	2008-07-10	2011-04-28	(주) 에이프로젠	동물세포용 재조합 발현벡터
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US20100021460A1 (en) *	2008-07-15	2010-01-28	Genentech, Inc.	Methods of Treating Autoimmune Diseases Using CD4 Antibodies
JP6049163B2 (ja) *	2008-07-21	2016-12-21	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	改善された治療上の特徴のための抗体の構造変異体
WO2010011281A2 (en) *	2008-07-22	2010-01-28	The Research Foundation Of State University Of New York	Methods and compositions for the diagnosis and treatment of cancer
MX2011001506A (es)	2008-08-14	2011-03-15	Genentech Inc	Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
MX2011002372A (es)	2008-09-10	2011-04-04	Genentech Inc	Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
TW201014605A (en) *	2008-09-16	2010-04-16	Genentech Inc	Methods for treating progressive multiple sclerosis
BRPI0914484A2 (pt) *	2008-10-28	2015-09-01	Avesthagen Ltd	Vetor de expressão e processos deste
CA2745271A1 (en) *	2008-12-04	2010-06-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
GB2466025A (en)	2008-12-08	2010-06-09	Univ Francois Rabelais De Tour	C3/ITGAM polymorphisms and cancer prognosis
EP2373689A1 (en)	2008-12-12	2011-10-12	MedImmune, LLC	Crystals and structure of a human igg fc variant with enhanced fcrn binding
ES2749232T3 (es)	2008-12-16	2020-03-19	Emd Millipore Corp	Reactor de tanque agitado y procedimiento
EP2358734A1 (en) *	2008-12-16	2011-08-24	Millipore Corporation	Purification of proteins
JP5810413B2 (ja)	2008-12-19	2015-11-11	バイオジェンインターナショナルニューロサイエンスゲーエムベーハー	ヒト抗アルファシヌクレイン自己抗体
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
KR101741168B1 (ko)	2008-12-22	2017-05-29	밀레니엄 파머슈티컬스 인코퍼레이티드	오로라 키나아제 억제제 및 항ｃｄ 항체의 병용
JP2012514458A (ja)	2008-12-31	2012-06-28	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗リンホトキシン抗体
US20110142836A1 (en) *	2009-01-02	2011-06-16	Olav Mella	B-cell depleting agents for the treatment of chronic fatigue syndrome
US20110275791A1 (en)	2009-01-06	2011-11-10	Ziad Mallat	A B Cell Depleting Agent for the Treatment of Atherosclerosis
JP5713923B2 (ja)	2009-02-27	2015-05-07	ジェネンテック，インコーポレイテッド	タンパク質標識方法及び組成物
KR101579771B1 (ko)	2009-03-05	2015-12-28	애브비 인코포레이티드	Ｉｌ-17 결합 단백질
PL2406284T3 (pl)	2009-03-10	2017-09-29	Biogen Ma Inc.	Przeciwciała anty-bcma
AU2010224125B2 (en)	2009-03-12	2015-05-14	Genentech, Inc.	Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
EP2233500A1 (en)	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
EP2411412B1 (en)	2009-03-24	2015-05-27	Teva Biopharmaceuticals USA, Inc.	Humanized antibodies against light and uses thereof
AR075982A1 (es)	2009-03-31	2011-05-11	Roche Glycart Ag	Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2435476A4 (en)	2009-05-27	2013-04-17	Synageva Biopharma Corp	ANTIBODIES OBTAINED FROM BIRDS
EP2443234B1 (en)	2009-06-15	2018-08-15	Icon Genetics GmbH	Nicotiana benthamiana plants deficient in xylosyltransferase activity
CN102802661B (zh)	2009-06-22	2016-01-13	米迪缪尼有限公司	用于位点特异性偶联的工程改造的Fc区
WO2011000543A1 (en) *	2009-06-30	2011-01-06	Philochem Ag	Murine antibody display library
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
AU2010282733B2 (en)	2009-08-11	2016-07-14	Genentech, Inc.	Production of proteins in glutamine-free cell culture media
TWI409079B (zh)	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
RU2012109451A (ru)	2009-08-14	2013-09-27	Роше Гликарт Аг	Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
AU2010289527C1 (en)	2009-09-01	2014-10-30	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
US9428548B2 (en)	2009-09-01	2016-08-30	Genentech, Inc.	Enhanced protein purification through a modified protein A elution
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012004777A2 (pt) *	2009-09-03	2019-09-24	Genentech Inc	métodos para tratar diagnósticar e monitorar artrite reumatoide
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
DK2486141T3 (en)	2009-10-07	2018-04-23	Macrogenics Inc	FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
MX2012004415A (es)	2009-10-15	2012-05-08	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX337290B (es) *	2009-10-19	2016-02-24	Hoffmann La Roche	Anticuerpos anti igg reactivos no cruzados.
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2325185A1 (en)	2009-10-28	2011-05-25	GPC Biotech AG	Plk inhibitor
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US20120309056A1 (en)	2010-02-04	2012-12-06	Leon Arnaud	Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011097527A2 (en)	2010-02-04	2011-08-11	Xencor, Inc.	Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) *	2010-02-04	2011-08-04	Xencor, Inc.	Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
US9175086B2 (en) *	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
RU2573994C2 (ru) *	2010-02-10	2016-01-27	Иммьюноджен, Инк	Антитела против cd20 и их применение
EP2543727B1 (en)	2010-03-02	2016-08-31	Kyowa Hakko Kirin Co., Ltd.	Modified antibody composition
WO2011109400A2 (en)	2010-03-04	2011-09-09	Macrogenics,Inc.	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en)	2010-03-04	2014-08-12	Macrogenics, Inc.	Antibodies reactive with B7-H3 and uses thereof
CA2792125C (en)	2010-03-22	2019-02-12	Genentech, Inc.	Compositions and methods useful for stabilizing protein-containing formulations
CA2793753C (en)	2010-03-26	2018-06-05	Memorial Sloan-Kettering Cancer Center	Antibodies to muc16 and methods of use thereof
EP2554669B1 (en)	2010-03-26	2018-09-19	Kyowa Hakko Kirin Co., Ltd.	Novel antibody having modification site introduced therein, and antibody fragment
WO2011120134A1 (en)	2010-03-29	2011-10-06	Zymeworks, Inc.	Antibodies with enhanced or suppressed effector function
WO2011123813A2 (en)	2010-04-02	2011-10-06	Amunix Operating Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US10338069B2 (en)	2010-04-12	2019-07-02	Academia Sinica	Glycan arrays for high throughput screening of viruses
CA2795544A1 (en)	2010-04-27	2011-11-03	Roche Glycart Ag	Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
WO2011139718A1 (en)	2010-05-03	2011-11-10	Genentech, Inc.	Compositions and methods useful for reducing the viscosity of protein-containing formulations
CN103068378B (zh)	2010-05-10	2016-07-06	中央研究院	具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
KR101539684B1 (ko)	2010-05-14	2015-07-27	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
SG184541A1 (en)	2010-05-17	2012-11-29	Emd Millipore Corp	Stimulus responsive polymers for the purification of biomolecules
JP5934190B2 (ja)	2010-05-25	2016-06-15	ジェネンテック，インコーポレイテッド	ポリペプチドの精製方法
PL2576580T3 (pl)	2010-05-28	2017-03-31	F.Hoffmann-La Roche Ag	Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
CN103068367B (zh)	2010-06-24	2016-09-07	弗·哈夫曼-拉罗切有限公司	用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
DK2591099T3 (da)	2010-07-09	2021-02-15	Bioverativ Therapeutics Inc	Kimære koagulationsfaktorer
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2409712A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en)	2010-07-19	2012-01-25	International-Drug-Development-Biotech	Anti-CD19 antibody having ADCC function with improved glycosylation profile
WO2012016227A2 (en)	2010-07-29	2012-02-02	Xencor, Inc.	Antibodies with modified isoelectric points
JPWO2012017925A1 (ja)	2010-08-02	2013-10-03	協和発酵キリン株式会社	物質の製造方法
KR20130045914A (ko)	2010-08-03	2013-05-06	에프. 호프만-라 로슈 아게	만성 림프구성 백혈병(cll) 생체지표
SG188190A1 (en)	2010-08-03	2013-04-30	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CN104474546A (zh)	2010-08-13	2015-04-01	弗·哈夫曼-拉罗切有限公司	用于疾病治疗的针对IL-1β和IL-18的抗体
BR112012033163A2 (pt) *	2010-08-17	2016-10-11	Hoffmann La Roche	''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
TW201208703A (en)	2010-08-17	2012-03-01	Roche Glycart Ag	Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
US9046513B2 (en)	2010-08-26	2015-06-02	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
PT3590949T (pt)	2010-10-01	2022-08-02	Modernatx Inc	Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
BR112013008765B8 (pt)	2010-10-11	2023-05-02	Biogen Idec Int Neuroscience Gmbh	Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
KR20130086628A (ko)	2010-11-08	2013-08-02	제넨테크, 인크.	피하 투여용 항―ｉｌ―6 수용체 항체
RU2598255C2 (ru)	2010-12-15	2016-09-20	Интер-Юниверсити Рисерч Инститьют Корпорейшн Рисерч Организейшн Оф Информейшн Энд Системз	Способ получения белка
CN103261229A (zh)	2010-12-16	2013-08-21	罗切格利卡特公司	无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
CA2818781C (en)	2010-12-17	2019-10-08	Neurimmune Holding Ag	Human anti-sod1 antibodies
MX2013007332A (es)	2010-12-21	2014-01-23	Abbvie Inc	Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
EP3147355B1 (en)	2010-12-27	2020-07-22	Kyowa Kirin Co., Ltd.	Method for preparing aqueous solution containing culture medium and chelating agent
WO2012095514A1 (en)	2011-01-14	2012-07-19	Vivalis	Recombinant protein production system
US9433686B2 (en)	2011-01-31	2016-09-06	The Regents Of The University Of California	Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
MX353143B (es)	2011-02-28	2017-12-20	Genentech Inc	Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
TWI588156B (zh)	2011-03-28	2017-06-21	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
LT2691417T (lt)	2011-03-29	2018-10-25	Roche Glycart Ag	Antikūno fc variantai
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
EP2506015A1 (en)	2011-04-01	2012-10-03	Universität Regensburg	A prognostic and therapeutic signature for malignant melanoma
DK2699598T3 (en)	2011-04-19	2019-04-23	Pfizer	COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
SI2707030T1 (sl)	2011-05-09	2020-10-30	Mayo Foundation For Medical Education And Research	Zdravljenje raka
RU2638806C2 (ru)	2011-05-12	2017-12-15	Дженентек, Инк.	Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
CN103842383B (zh)	2011-05-16	2017-11-03	健能隆医药技术（上海）有限公司	多特异性fab融合蛋白及其使用方法
NZ618016A (en)	2011-05-21	2015-05-29	Macrogenics Inc	Deimmunized serum-binding domains and their use for extending serum half-life
PT2714733T (pt)	2011-05-21	2019-05-23	Macrogenics Inc	Moléculas de ligação a cd3 com capacidade para ligar a cd3 humana e não humana
RU2011122942A (ru)	2011-06-08	2012-12-20	Общество С Ограниченной Ответственностью "Асинэкс Медхим"	Новые ингибиторы киназ
DK2723379T3 (en)	2011-06-23	2018-10-15	Biogen Int Neuroscience Gmbh	ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
EP2537933A1 (en)	2011-06-24	2012-12-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012280267B2 (en)	2011-07-06	2016-04-21	Morphosys Ag	Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
US20130012689A1 (en)	2011-07-08	2013-01-10	Emd Millipore Corporation	Depth Filters For Disposable Biotechnological Processes
WO2013009868A1 (en)	2011-07-11	2013-01-17	Yale University	Compositions and methods for making selenocysteine containing polypeptides
WO2019071023A1 (en)	2017-10-04	2019-04-11	Yale University	COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
WO2013012733A1 (en)	2011-07-15	2013-01-24	Biogen Idec Ma Inc.	Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP2551348B1 (en)	2011-07-29	2014-09-24	Icon Genetics GmbH	Production of galactosylated N-glycans in plants
EP2550975A1 (en)	2011-07-29	2013-01-30	Sanofi	Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US20140234307A1 (en)	2011-09-27	2014-08-21	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
RU2648950C2 (ru)	2011-10-03	2018-04-02	Модерна Терапьютикс, Инк.	Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2764105B1 (en)	2011-10-04	2017-03-15	Icon Genetics GmbH	Nicotiana benthamiana plants deficient in fucosyltransferase activity
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA3182462A1 (en)	2011-10-10	2013-04-18	Xencor, Inc.	A method for purifying antibodies
TW201323440A (zh)	2011-10-24	2013-06-16	Abbvie Inc	抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
JP6316195B2 (ja)	2011-10-26	2018-04-25	エランコティーアゲズンタイトアーゲー	モノクローナル抗体および使用の方法
US20130302274A1 (en)	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
RS63244B1 (sr)	2011-12-16	2022-06-30	Modernatx Inc	Kompozicije modifikovane mrna
RU2648999C2 (ru)	2011-12-22	2018-03-29	Дженентек, Инк.	Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
CN104159920A (zh)	2011-12-30	2014-11-19	艾伯维公司	针对il-13和/或il-17的双重可变结构域免疫球蛋白
CA2863066A1 (en)	2012-01-31	2013-08-08	Genentech, Inc.	Anti-ig-e m1' antibodies and methods using same
RU2659423C2 (ru)	2012-02-16	2018-07-02	ЭйТИР ФАРМА, ИНК.	ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
SG10202007206WA (en)	2012-03-27	2020-08-28	Genentech Inc	Improved harvest operations for recombinant proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
WO2013151664A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins
US9303079B2 (en)	2012-04-02	2016-04-05	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013262934B2 (en)	2012-05-14	2018-02-01	Biogen Ma Inc.	LINGO-2 antagonists for treatment of conditions involving motor neurons
SG11201408161RA (en)	2012-06-08	2015-01-29	Sutro Biopharma Inc	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2863940A4 (en)	2012-06-08	2016-08-10	Biogen Ma Inc	CHIMERIC COAGULATION FACTORS
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
SI3495387T1 (sl)	2012-07-13	2021-12-31	Roche Glycart Ag	Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
JP6302909B2 (ja)	2012-08-18	2018-03-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	シアリダーゼの同定および画像化のための細胞透過性プローブ
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
JP6826367B2 (ja)	2012-08-31	2021-02-03	ストロバイオファーマインコーポレーテッド	アジド基を含む修飾アミノ酸
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052713A2 (en)	2012-09-27	2014-04-03	Massachusetts Institute Of Technology	Her2-and vegf-a-binding proteins with enhanced stability
EP3967306A1 (en)	2012-10-01	2022-03-16	Mayo Foundation for Medical Education and Research	Cancer treatments
MX2015004436A (es)	2012-10-09	2015-06-24	Biogen Idec Inc	Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
CA2941485C (en)	2012-10-12	2018-06-12	Philip Wilson Howard	Pyrrolobenzodiazepines and conjugates thereof
US9163093B2 (en)	2012-11-01	2015-10-20	Abbvie Inc.	Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
KR20150079866A (ko)	2012-11-01	2015-07-08	애브비 인코포레이티드	안정한 이중 가변 도메인 면역글로불린 단백질 제제
KR102341275B1 (ko)	2012-11-02	2021-12-21	티지 쎄라퓨틱스, 인코포레이티드	항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
RS63237B1 (sr)	2012-11-26	2022-06-30	Modernatx Inc	Terminalno modifikovana rnk
WO2014100095A1 (en)	2012-12-19	2014-06-26	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
EA035932B1 (ru)	2012-12-21	2020-09-02	Байоджен Ма Инк.	Человеческие анти-тау антитела
CA2896824A1 (en)	2012-12-31	2014-07-03	Neurimmune Holding Ag	Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
DK2943511T3 (da)	2013-01-14	2019-10-21	Xencor Inc	Nye heterodimeriske proteiner
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
CA2897987A1 (en)	2013-01-15	2014-07-24	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
KR101763345B1 (ko) *	2013-01-24	2017-08-14	주식회사 앱틀라스	단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법
JP2016513098A (ja)	2013-02-07	2016-05-12	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
DK3889173T5 (da)	2013-02-15	2024-08-05	Bioverativ Therapeutics Inc	Optimeret faktor viii-gen
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6511609B2 (ja)	2013-03-13	2019-05-22	ジェネンテック，インコーポレイテッド	抗体製剤
BR112015023333A8 (pt)	2013-03-13	2018-04-17	Medimmune Ltd	pirrolbenzodiazepinas e conjugados dos mesmos
CN105189561B (zh)	2013-03-14	2021-02-26	宏观基因有限公司	与表达激活受体的免疫效应细胞和由被病毒感染的细胞表达的抗原具有免疫反应性的双特异性分子及其用途
DK2970486T3 (en)	2013-03-15	2018-08-06	Xencor Inc	MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
CA2904528C (en)	2013-03-15	2021-01-19	Abbvie Biotherapeutics Inc.	Fc variants
WO2014144280A2 (en)	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
SG11201505926VA (en)	2013-03-15	2015-09-29	Biogen Ma Inc	Factor ix polypeptide formulations
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
JP6433085B2 (ja)	2013-04-09	2018-12-05	ボストンバイオメディカル，インコーポレイテッド	がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
CN105324124A (zh)	2013-04-19	2016-02-10	赛腾制药	降低的血管渗漏综合征的细胞因子衍生治疗
EP2805730A1 (en)	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2014190441A1 (en)	2013-05-31	2014-12-04	Zymeworks Inc.	Heteromultimers with reduced or silenced effector function
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
EP3013347B1 (en)	2013-06-27	2019-12-11	Academia Sinica	Glycan conjugates and use thereof
EP3336103B1 (en)	2013-07-10	2021-03-17	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3041484B1 (en)	2013-09-06	2021-03-03	Academia Sinica	Human inkt cell activation using glycolipids with altered glycosyl groups
CA2923843C (en)	2013-09-11	2022-07-12	Arsia Therapeutics, Inc.	Liquid protein formulations containing water soluble organic dyes
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
EP3055298B1 (en)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN105813637A (zh)	2013-11-01	2016-07-27	卑尔根技术转移公司	用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
CA2963178C (en)	2013-11-12	2023-01-24	Ogd2 Pharma	Human igg1 derived antibody with pro-apoptotic activity
BR112016013741A2 (pt)	2013-12-17	2017-10-03	Genentech Inc	Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US9982041B2 (en)	2014-01-16	2018-05-29	Academia Sinica	Compositions and methods for treatment and detection of cancers
CN106029098A (zh)	2014-02-25	2016-10-12	免疫医疗公司	人源化rfb4抗cd22抗体
EP2915569A1 (en)	2014-03-03	2015-09-09	Cytune Pharma	IL-15/IL-15Ralpha based conjugates purification method
TWI754319B (zh)	2014-03-19	2022-02-01	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
AU2015237184B2 (en)	2014-03-28	2020-11-26	Xencor, Inc.	Bispecific antibodies that bind to CD38 and CD3
WO2015164758A1 (en)	2014-04-25	2015-10-29	University Of Florida Research Foundation, Inc.	Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
KR20240096599A (ko)	2014-05-27	2024-06-26	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
DK3149045T3 (da)	2014-05-27	2023-03-06	Academia Sinica	Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
JP7062361B2 (ja)	2014-05-27	2022-05-06	アカデミアシニカ	抗ｈｅｒ２糖操作抗体群およびその使用
JP7063538B2 (ja)	2014-05-28	2022-05-09	アカデミアシニカ	抗ＴＮＦα糖操作抗体群およびその使用
CN106573051B (zh)	2014-06-13	2021-07-13	梅约医药教育及研究基金会	治疗淋巴瘤
JP6600651B2 (ja)	2014-06-16	2019-10-30	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	骨髄腫の治療
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
CN106686977B (zh)	2014-07-09	2022-03-25	豪夫迈·罗氏有限公司	Ph调整以改善细胞库的解冻复苏
CN107074937B (zh)	2014-07-29	2021-07-27	神经免疫控股公司	人源抗亨廷顿蛋白(htt)抗体及其用途
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
EP3567056A1 (en)	2014-09-10	2019-11-13	F. Hoffmann-La Roche AG	Galactoengineered immunoglobulin 1 antibodies
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
ES2949173T3 (es)	2014-09-15	2023-09-26	Hoffmann La Roche	Formulaciones de anticuerpo
HUE049175T2 (hu)	2014-09-23	2020-09-28	Hoffmann La Roche	Eljárás anti-CD79b immunkonjugátumok alkalmazására
AU2015323860B2 (en)	2014-09-29	2021-05-27	Duke University	Bispecific molecules comprising an HIV-1 envelope targeting arm
IL278941B (en)	2014-09-30	2022-07-01	Neurimmune Holding Ag	dprs antibodies which originate in the human body
CN106999510B (zh)	2014-10-01	2021-04-30	伊格尔生物制品有限公司	含有粘度降低剂的多糖和核酸制剂
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
MA40835A (fr)	2014-10-23	2017-08-29	Biogen Ma Inc	Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Anticorps anti-glycoprotéines iib/iiia
LT3221359T (lt)	2014-11-17	2020-07-27	Regeneron Pharmaceuticals, Inc.	Naviko gydymo būdai, naudojant cd3xcd20 bispecifinį antikūną
PE20171103A1 (es)	2014-11-26	2017-08-07	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cd38
NZ732144A (en)	2014-11-26	2020-04-24	Xencor Inc	Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
WO2016112270A1 (en)	2015-01-08	2016-07-14	Biogen Ma Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
AU2015378564A1 (en)	2015-01-24	2017-07-13	Academia Sinica	Novel glycan conjugates and methods of use thereof
WO2016141387A1 (en)	2015-03-05	2016-09-09	Xencor, Inc.	Modulation of t cells with bispecific antibodies and fc fusions
US10722523B2 (en)	2015-03-17	2020-07-28	The Regents Of The University Of California	Chemoimmunotherapy for epithelial cancer
ES2929614T3 (es)	2015-03-17	2022-11-30	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-MUC16 y usos de los mismos
CN107592812A (zh)	2015-05-11	2018-01-16	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
ES2847373T3 (es)	2015-05-30	2021-08-03	Molecular Templates Inc	Estructuras de subunidad A de toxina Shiga desinmunizadas y molécula de reconocimiento celular que las comprenden
BR112017026025A2 (pt)	2015-06-03	2018-08-14	Boston Biomedical Inc	composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3108897A1 (en)	2015-06-24	2016-12-28	F. Hoffmann-La Roche AG	Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
CR20210429A (es)	2015-06-24	2021-09-24	Hoffmann La Roche	ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
AU2016285596A1 (en)	2015-06-29	2018-01-18	Genentech, Inc.	Type II anti-CD20 antibody for use in organ transplantation
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
LT3334747T (lt)	2015-08-13	2023-12-27	Amgen Inc.	Įkrautas giluminis antigeną surišančio baltymo filtravimas
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
WO2017040344A2 (en)	2015-08-28	2017-03-09	Amunix Operating Inc.	Chimeric polypeptide assembly and methods of making and using the same
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr)	2015-10-02	2018-08-08	Hoffmann La Roche	Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017078839A1 (en)	2015-11-02	2017-05-11	Bioatla, Llc	Conditionally active polypeptides
AU2016365742A1 (en)	2015-12-07	2018-06-21	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and PSMA
KR20180098625A (ko)	2015-12-30	2018-09-04	제넨테크, 인크.	분해가 감소된 폴리소르베이트를 갖는 제형
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
AU2017214378B2 (en)	2016-02-01	2023-05-04	Bioverativ Therapeutics Inc.	Optimized Factor VIII genes
WO2017139698A1 (en)	2016-02-12	2017-08-17	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
EP3423491A1 (en)	2016-03-01	2019-01-09	H. Hoffnabb-La Roche Ag	Obinutuzumab variants having altered cell death induction
WO2017149018A1 (en)	2016-03-02	2017-09-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
US10336784B2 (en)	2016-03-08	2019-07-02	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
SG11201807949WA (en)	2016-03-14	2018-10-30	Univ Oslo	Engineered immunoglobulins with altered fcrn binding
WO2017157305A1 (en)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Multispecific fab fusion proteins and use thereof
CA3018340A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
WO2017165440A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
EP3436610A1 (en)	2016-03-29	2019-02-06	Geltor, Inc.	Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
JP7002467B2 (ja)	2016-04-15	2022-01-20	マクロジェニクス，インコーポレーテッド	新規のｂ７‐ｈ３結合分子、その抗体薬物コンジュゲート、及びその使用方法
WO2017182608A1 (en)	2016-04-22	2017-10-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and vaccine compositions for the treatment of b-cell malignancies
CN109640964A (zh)	2016-05-27	2019-04-16	Tg治疗有限公司	用于治疗B细胞增殖性紊乱的抗-CD20抗体、P13激酶-δ选择性抑制剂和BTK抑制剂的组合
EP3468586B1 (en)	2016-06-14	2024-08-07	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
EP3472197A1 (en)	2016-06-15	2019-04-24	Sutro Biopharma, Inc.	Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
AU2017290086A1 (en)	2016-06-28	2019-01-24	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3484512A1 (en)	2016-07-13	2019-05-22	Biogen MA Inc.	Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
GB201613167D0 (en)	2016-07-29	2016-09-14	Univ Southampton	Cancer and b-cell related disease therapy
CA3034057A1 (en)	2016-08-22	2018-03-01	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh)	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
KR20190053203A (ko)	2016-09-01	2019-05-17	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	Ｔ－세포 암을 표적화하는 방법 및 조성물
EP4177271A1 (en)	2016-09-01	2023-05-10	Mayo Foundation for Medical Education and Research	Carrier-pd-l1 binding agent compositions for treating cancers
KR20230011473A (ko)	2016-09-06	2023-01-20	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3509635A1 (en)	2016-09-06	2019-07-17	Vavotar Life Sciences LLC	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR102486055B1 (ko)	2016-09-06	2023-01-09	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
BR112019004185A2 (pt)	2016-09-09	2019-09-03	Lab Francais Du Fractionnement	combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
CN108421048B (zh) *	2016-09-28	2021-04-20	首都医科大学附属北京世纪坛医院	纳米活性碳靶向药物递送系统、制备方法及其用途
US20200023072A1 (en)	2016-10-11	2020-01-23	Medimmune Limited	Antibody-drug conjugates with immune-mediated therapy agents
US10550185B2 (en)	2016-10-14	2020-02-04	Xencor, Inc.	Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US11299469B2 (en)	2016-11-29	2022-04-12	Sumitomo Dainippon Pharma Oncology, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
EP3548896B1 (en)	2016-12-01	2021-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
WO2018102760A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
CR20190389A (es)	2017-01-31	2019-11-26	Bioverativ Therapeutics Inc	Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas
GB201703876D0 (en)	2017-03-10	2017-04-26	Berlin-Chemie Ag	Pharmaceutical combinations
CN110352201A (zh)	2017-04-03	2019-10-18	免疫医疗公司	用于癌症疗法的抗体药物缀合物的皮下施用
WO2018211517A1 (en)	2017-05-16	2018-11-22	Bhami's Research Laboratory, Pvt. Ltd.	High concentration protein formulations with reduced viscosity
WO2018213424A1 (en)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methods for treating cancer
CN111132733A (zh)	2017-06-30	2020-05-08	Xencor股份有限公司	含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
EA202090020A1 (ru)	2017-07-10	2020-04-28	Интернэшнл - Драг - Дивелопмент - Байотек	Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
JP2020528061A (ja)	2017-07-26	2020-09-17	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
US10759865B2 (en)	2017-08-22	2020-09-01	Eyal Levit	Treatment of diabetes mellitus
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (en)	2017-10-20	2019-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en)	2017-11-08	2022-04-26	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN111655718A (zh)	2017-12-19	2020-09-11	Xencor股份有限公司	经过工程化的il-2 fc融合蛋白
EP3765489B1 (en)	2018-03-13	2024-10-16	F. Hoffmann-La Roche AG	Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies
EA202092316A1 (ru)	2018-03-28	2021-05-25	Бристол-Маерс Сквибб Компани	Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
EP3773911A2 (en)	2018-04-04	2021-02-17	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
WO2019204655A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020010910A (es)	2018-04-18	2021-02-09	Xencor Inc	Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
SG11202010154UA (en)	2018-04-18	2020-11-27	Ucl Business Ltd	Method for enhancing the suppressive properties of treg cells
JP2021524449A (ja)	2018-05-23	2021-09-13	アーデーセーセラピューティクスソシエテアノニム	分子アジュバント
KR20210027427A (ko)	2018-07-03	2021-03-10	브리스톨-마이어스 스큅 컴퍼니	재조합 단백질 생산 방법
EP3820475A4 (en)	2018-07-09	2022-04-13	Takeda Pharmaceutical Company Limited	ADMINISTRATION OF SUMO-ACTIVATING ENZYMIN HIBITOR AND ANTI-CD20 ANTIBODIES
US20210186880A1 (en)	2018-08-03	2021-06-24	Brown University	Oral formulations with increased uptake
CN109273050B (zh) *	2018-08-03	2021-07-13	五邑大学	一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
US11590223B2 (en)	2018-08-31	2023-02-28	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
AU2019344795A1 (en)	2018-09-17	2021-03-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bicistronic chimeric antigen receptors targeting CD19 and CD20 and their uses
CN113195523A (zh)	2018-10-03	2021-07-30	Xencor股份有限公司	IL-12异源二聚体Fc融合蛋白
GB201816554D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
GB201816553D0 (en)	2018-10-10	2018-11-28	Centauri Therapeutics Ltd	Novel compounds and therapeutic uses thereof
MA53859A (fr)	2018-10-10	2022-01-19	Boehringer Ingelheim Int	Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
WO2020076849A1 (en)	2018-10-11	2020-04-16	The Scripps Research Institute	Antibody compounds with reactive arginine and related antibody drug conjugates
EP3868784A4 (en)	2018-10-15	2022-07-27	Industry-Academic Cooperation Foundation, Yonsei University	ANTIBODIES WITH INCREASED PRODUCTIVITY AND METHODS FOR THEIR PRODUCTION
RU2724469C2 (ru)	2018-10-31	2020-06-23	Закрытое Акционерное Общество "Биокад"	Моноклональное антитело, которое специфически связывается с cd20
EP3875595A4 (en)	2018-11-02	2022-07-13	Kyowa Kirin Co., Ltd.	METHOD FOR PREPARING LIQUID CULTURE MEDIUM
US20220016277A1 (en)	2018-11-20	2022-01-20	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CA3119798A1 (en)	2018-12-06	2020-06-11	Genentech, Inc.	Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
EP3891270A1 (en)	2018-12-07	2021-10-13	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
JP2022523510A (ja)	2019-01-31	2022-04-25	エレクトロフィ，インコーポレイテッド	粒子形成及び形態構造
CA3130103A1 (en)	2019-02-13	2020-08-20	The Brigham And Women's Hospital, Inc.	Anti-peripheral lymph node addressin antibodies and uses thereof
BR112021016348A2 (pt)	2019-02-18	2021-11-23	Atb Therapeutics	Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
KR20210133237A (ko)	2019-02-27	2021-11-05	제넨테크, 인크.	항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
JP2022523946A (ja)	2019-03-01	2022-04-27	ゼンコアインコーポレイテッド	Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
EP3946457A1 (en)	2019-04-01	2022-02-09	Genentech, Inc.	Compositions and methods for stabilizing protein-containing formulations
SG11202111349QA (en)	2019-04-12	2021-11-29	Geltor Inc	Recombinant elastin and production thereof
TW202108178A (zh)	2019-05-14	2021-03-01	美商建南德克公司	使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
EP3980423A1 (en)	2019-06-10	2022-04-13	Sutro Biopharma, Inc.	5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
WO2020257235A1 (en)	2019-06-17	2020-12-24	Sutro Biopharma, Inc.	1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US20220315887A1 (en)	2019-08-01	2022-10-06	Bristol-Myers Squibb Company	Methods of improving protein productivity in fed-batch cell cultures
JP2022546686A (ja)	2019-08-30	2022-11-07	ベストランデツイノバシオンセルスカップアーエス	形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法
EP4028054A1 (en)	2019-09-12	2022-07-20	Genentech, Inc.	Compositions and methods of treating lupus nephritis
CN114514035A (zh)	2019-09-13	2022-05-17	伊勒卓菲公司	递送用于治疗疾病的治疗性生物制剂的组合物和方法
CN118557750A (zh)	2019-10-18	2024-08-30	基因泰克公司	使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
US20230022576A1 (en)	2019-11-19	2023-01-26	Protalix Ltd.	Removal of constructs from transformed cells
JP2023512084A (ja)	2020-01-31	2023-03-23	シージェンインコーポレイテッド	抗ｃｄ３０抗体薬物コンジュゲート及び非ホジキンリンパ腫の治療のためのその使用
US20230065628A1 (en)	2020-02-19	2023-03-02	Elektrofi, Inc.	Droplet Formation and Particle Morphology
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN115484934A (zh)	2020-04-17	2022-12-16	伊勒卓菲公司	通过连续液滴形成和脱水形成颗粒的方法
KR20230005903A (ko)	2020-04-24	2023-01-10	제넨테크, 인크.	항-CD79b 면역접합체를 사용하는 방법
KR20230005841A (ko)	2020-04-26	2023-01-10	바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드	변형된 면역글로불린
US20230293709A1 (en)	2020-05-03	2023-09-21	Shanghai Miracogen Inc.	Antibody-drug conjugate and preparation thereof
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
GB202007842D0 (en)	2020-05-26	2020-07-08	Quell Therapeutics Ltd	Polypeptide useful in adoptive cell therapy
EP4189121A1 (en)	2020-08-03	2023-06-07	Genentech, Inc.	Diagnostic and therapeutic methods for lymphoma
GB202012331D0 (en)	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
WO2022040482A1 (en)	2020-08-19	2022-02-24	Xencor, Inc.	Anti-cd28 and/or anti-b7h3 compositions
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (en)	2020-08-27	2022-03-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
GB202013477D0 (en)	2020-08-27	2020-10-14	Quell Therapeutics Ltd	Nucleic acid constructs for expressing polypeptides in cells
JP2023541860A (ja)	2020-09-10	2023-10-04	ジェンマブエー／エス	びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
MX2023002540A (es)	2020-09-10	2023-03-14	Genmab As	Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
CA3192255A1 (en)	2020-09-10	2022-03-17	Brian Elliott	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
WO2022053656A1 (en)	2020-09-10	2022-03-17	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
IL301096A (en)	2020-09-10	2023-05-01	Genmab As	Bispecific antibodies against CD3 and CD20 for the treatment of chronic lymphocytic leukemia
JP2023542924A (ja)	2020-09-22	2023-10-12	ブリストル－マイヤーズスクイブカンパニー	治療タンパク質を生産するための方法
JP2023545999A (ja)	2020-10-05	2023-11-01	プロタリクスリミテッド	ダイサー（ｄｉｃｅｒ）様ノックアウト植物細胞
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
WO2022103983A2 (en)	2020-11-11	2022-05-19	Sutro Biopharma, Inc.	Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US20220143026A1 (en)	2020-11-12	2022-05-12	Tg Therapeutics, Inc.	Triple combination to treat b-cell malignancies
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
MX2023010499A (es)	2021-03-09	2023-09-18	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cldn6.
US11859012B2 (en)	2021-03-10	2024-01-02	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and GPC3
EP4454652A2 (en)	2021-03-15	2024-10-30	F. Hoffmann-La Roche AG	Compositions and methods for treating lupus nephritis
WO2022204282A1 (en)	2021-03-24	2022-09-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
US20240207464A1 (en)	2021-04-20	2024-06-27	Nihon Medi-Physics Co., Ltd.	Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
EP4334354A1 (en)	2021-05-06	2024-03-13	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
IL308351A (en)	2021-05-12	2024-01-01	Genentech Inc	Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
US20240270862A1 (en)	2021-06-01	2024-08-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of b cell depleting agents for the treatment of rheumatic heart disease
MX2023014195A (es)	2021-06-08	2024-01-18	Xyphos Biosciences Inc	Proteina de fusion de anticuerpo con dominio del ligando de nkg2d.
BR112023025884A2 (pt)	2021-06-08	2024-02-27	Xyphos Biosciences Inc	Proteína de fusão de domínio de ligante de anticorpo de nkg2d
EP4355779A1 (en)	2021-06-17	2024-04-24	Glaxosmithkline Intellectual Property Limited	Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
AU2022294198A1 (en)	2021-06-17	2023-12-21	Petmedix Ltd	Anti canine cd20 antibodies
JP2024527977A (ja)	2021-07-27	2024-07-26	ノヴァブ，インコーポレイテッド	免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023015234A1 (en)	2021-08-05	2023-02-09	Bristol-Myers Squibb Company	Cell culture methods for producing therapeutic proteins
WO2023012486A1 (en)	2021-08-06	2023-02-09	Petmedix Ltd	Antibody fc variants
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
KR20240049825A (ko)	2021-08-23	2024-04-17	바이오버라티브 테라퓨틱스 인크.	역위 말단 반복부 서열을 사용한 닫힌 말단 dna 제조
TW202323274A (zh)	2021-08-23	2023-06-16	美商百歐維拉提夫治療公司	優化因子viii基因
WO2023049687A1 (en)	2021-09-21	2023-03-30	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4408874A1 (en)	2021-09-30	2024-08-07	Bioverativ Therapeutics Inc.	Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
TW202321308A (zh)	2021-09-30	2023-06-01	美商建南德克公司	使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
AU2022396272A1 (en)	2021-11-24	2024-06-06	Dana-Farber Cancer Institute, Inc.	Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
CA3241407A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
KR20240144239A (ko)	2022-01-28	2024-10-02	젠맵 에이/에스	미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2023150552A1 (en)	2022-02-04	2023-08-10	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treatment of neurological disorders
IL314314A (en)	2022-02-09	2024-09-01	Petmedix Ltd	Therapeutic antibodies
WO2023164487A1 (en)	2022-02-22	2023-08-31	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2023198635A1 (en)	2022-04-11	2023-10-19	Astrazeneca Ab	T cell binding proteins
WO2023212721A1 (en)	2022-04-29	2023-11-02	Elektrofi, Inc.	Injectable suspensions
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
WO2024006272A1 (en)	2022-06-27	2024-01-04	Sutro Biopharma, Inc.	β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
WO2024015229A1 (en)	2022-07-15	2024-01-18	Sutro Biopharma, Inc.	Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024039672A2 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
WO2024039670A1 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024153636A1 (en)	2023-01-17	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Vasorin as a biomarker and biotarget in nephrology
WO2024182516A1 (en)	2023-02-28	2024-09-06	Juno Therapeutics, Inc.	Cell therapy for treating systemic autoimmune diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US163708A (en) *		1875-05-25		Improvement in harvester-rakes
US95963A (en) *		1869-10-19		Improvement in fence
US147885A (en) *		1874-02-24		Improvement in the manufacture of halters and bridles
US197255A (en) *		1877-11-20		Improvement in receivers and stench-traps for street-sewers
US213784A (en) *		1879-04-01		Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US186205A (en) *		1877-01-16		Improvement in buffing-rolls for thesoles of boots andshoes
US21781A (en) *		1858-10-12		Improved method o f lighting street-lamps by electricity
US26804A (en) *		1860-01-10		Bridle-bit
US206903A (en) *		1878-08-13		Improvement in cultivators
US9444A (en) *		1852-12-07		Hot-air furnace
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0173494A3 (en) *	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
USRE38008E1 (en) *	1986-10-09	2003-02-25	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) *	1986-10-27	2005-05-17	Royalty Pharma Finance Trust	Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) *	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) *	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5439665A (en) *	1988-07-29	1995-08-08	Immunomedics	Detection and treatment of infectious and inflammatory lesions
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH06501705A (ja) *	1990-11-05	1994-02-24	ブリストル−マイアーズ　スクイブ　カンパニー	抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
MX9204374A (es) *	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JP3095175B2 (ja) *	1992-11-13	2000-10-03	アイデックファーマシューティカルズコーポレイション	Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) *	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) *	1995-06-07	1997-10-14	Hughes Electronics	Communication system and method providing dispatch and cellular interconnect communications
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies

1993
- 1993-11-03 US US08/149,099 patent/US5736137A/en not_active Expired - Lifetime
- 1993-11-12 CN CN2006100900848A patent/CN101007851B/zh not_active Expired - Lifetime
- 1993-11-12 ES ES08013898T patent/ES2326144T3/es not_active Expired - Lifetime
- 1993-11-12 CN CNB931214246A patent/CN1270774C/zh not_active Expired - Lifetime
- 1993-11-12 DE DE69334259T patent/DE69334259D1/de not_active Expired - Lifetime
- 1993-11-12 EP EP08013898A patent/EP2000149B1/en not_active Expired - Lifetime
- 1993-11-12 AT AT99123967T patent/ATE421335T1/de active
- 1993-11-12 PL PL93320526A patent/PL175557B1/pl unknown
- 1993-11-12 DK DK08013898T patent/DK2000149T3/da active
- 1993-11-12 DK DK99123967T patent/DK1005870T3/da active
- 1993-11-12 CA CA002626445A patent/CA2626445A1/en not_active Withdrawn
- 1993-11-12 ZA ZA938466A patent/ZA938466B/xx unknown
- 1993-11-12 AT AT08013898T patent/ATE431158T1/de active
- 1993-11-12 CN CN2006100900829A patent/CN1912111B/zh not_active Expired - Lifetime
- 1993-11-12 ES ES99123967T patent/ES2321567T3/es not_active Expired - Lifetime
- 1993-11-12 MY MYPI93002374A patent/MY111196A/en unknown
- 1993-11-12 CN CN200610090080XA patent/CN101007850B/zh not_active Expired - Lifetime
- 1993-11-12 DE DE69334285T patent/DE69334285D1/de not_active Expired - Lifetime
- 1993-11-12 HU HU9501410A patent/HU219264B/hu active Protection Beyond IP Right Term
- 1993-11-12 IL IL10759193A patent/IL107591A/xx not_active IP Right Cessation
- 1993-11-12 DE DE122009000070C patent/DE122009000070I1/de active Pending
- 1993-11-12 PT PT08013898T patent/PT2000149E/pt unknown
- 1993-11-12 CN CN2004100488083A patent/CN1607006B/zh not_active Expired - Lifetime
- 1993-11-12 KR KR1019950701928A patent/KR100365632B1/ko not_active IP Right Cessation
- 1993-11-12 UA UA95062664A patent/UA27946C2/uk unknown
- 1993-11-12 SG SG1996002951A patent/SG45294A1/en unknown
- 1993-11-12 PT PT99123967T patent/PT1005870E/pt unknown
- 1993-12-14 TW TW082110578A patent/TW376320B/zh not_active IP Right Cessation
1997
- 1997-05-13 BR BR1100622-6A patent/BR1100622A/pt active IP Right Grant
2002
- 2002-03-14 US US10/096,964 patent/US20030082172A1/en not_active Abandoned
2004
- 2004-07-15 FR FR04C0018C patent/FR04C0018I2/fr active Active
2006
- 2006-07-07 GE GEAP20069498A patent/GEP20074162B/en unknown
2008
- 2008-01-11 HK HK08100410.4A patent/HK1109634A1/xx not_active IP Right Cessation
- 2008-01-11 HK HK08100409.7A patent/HK1109633A1/xx not_active IP Right Cessation
2009
- 2009-05-13 HK HK09104369.6A patent/HK1125574A1/xx not_active IP Right Cessation
- 2009-11-10 NL NL300424C patent/NL300424I1/nl unknown
- 2009-11-11 LU LU91620C patent/LU91620I2/fr unknown
2010
- 2010-01-06 GE GEAP200911620A patent/GEPI20105119B/en unknown
- 2010-01-06 GE GEAP201011620A patent/GEP20105119B/en unknown

Also Published As

Publication number	Publication date
IL107591A0 (en)	1994-02-27
ATE431158T1 (de)	2009-05-15
DK2000149T3 (da)	2009-08-03
CN101007851B (zh)	2012-09-12
GEP20074162B (en)	2007-07-10
FR04C0018I1 (xx)	2008-09-26
CN1094965A (zh)	1994-11-16
MY111196A (en)	1999-09-30
ES2326144T3 (es)	2009-10-01
PT2000149E (pt)	2009-07-14
US20030082172A1 (en)	2003-05-01
HU9501410D0 (en)	1995-06-28
EP2000149A1 (en)	2008-12-10
DE122009000070I1 (de)	2010-02-11
LU91620I2 (fr)	2010-01-11
CN1270774C (zh)	2006-08-23
CN101007850B (zh)	2012-05-30
CN101007851A (zh)	2007-08-01
NL300424I1 (nl)	2010-01-04
ATE421335T1 (de)	2009-02-15
BR1100622A (pt)	2000-04-18
PL175557B1 (pl)	1999-01-29
FR04C0018I2 (xx)	2009-11-20
CN101007850A (zh)	2007-08-01
EP2000149B1 (en)	2009-05-13
DE69334259D1 (de)	2009-03-12
CN1607006B (zh)	2012-09-19
KR100365632B1 (ko)	2003-08-02
CN1912111A (zh)	2007-02-14
CN1607006A (zh)	2005-04-20
PT1005870E (pt)	2009-04-28
HK1125574A1 (en)	2009-08-14
DK1005870T3 (da)	2009-05-18
HK1109633A1 (en)	2008-06-13
SG45294A1 (en)	1998-01-16
GEPI20105119B (en)	2010-11-25
DE69334285D1 (de)	2009-06-25
IL107591A (en)	2000-02-17
US5736137A (en)	1998-04-07
GEP20105119B (en)	2010-11-25
HUT72914A (en)	1996-06-28
ES2321567T3 (es)	2009-06-08
TW376320B (en)	1999-12-11
ZA938466B (en)	1994-06-20
UA27946C2 (uk)	2000-10-16
CA2626445A1 (en)	1994-05-26
HU219264B (en)	2001-03-28
CN1912111B (zh)	2010-05-26

Publication	Publication Date	Title
HK1109633A1 (en)	2008-06-13	Chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen
GR3020731T3 (en)	1996-11-30	Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma.

Legal Events

Date	Code	Title	Description
2013-03-08	CORR	Corrigendum	Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20080613: (71) BIOGEN IDEC INC.
2013-12-13	PE	Patent expired	Effective date: 20131111